Evaluating Multi-Drug Screening Test Cross-Reactivity Data: Questions to Ask Your Supplier

JAL Medical’s iCARE Multi-Drug Screening Test Range at a Glance

The iCARE One Step Multi-Drug Screening Test from JAL Medical is a rapid, qualitative, competitive lateral flow immunoassay. It is intended to detect drugs of abuse (DOA) and/or their metabolites in human urine, with 1 to 14 drug indicators detected in a single step. JAL Medical lists the following indicators:

• Amphetamines (AMP), Methamphetamine (MET) and MDMA
• Benzodiazepines (BZO) and Barbiturates (BAR)
• Cocaine (COC) and Phencyclidine (PCP)
• Opiates (Morphine, OPI), Methadone (MTD), Buprenorphine (BUP) and Tramadol (TRA)
• THC (Marijuana), Tricyclic Antidepressants (TCA) and Ketamine (KET)

The test is available in three formats, each with its own reference codes: strips (110901S–110914S), cards (110901D–110914D) and cups (110901C–110914C). The brochure illustrates a Multi-6 card and a Multi-11 cup, showing that panel composition varies by configuration.

Matching Drug Screening Test Cross-Reactivity Evidence to the Selected Configuration

With so many combinations available, drug screening test cross-reactivity evidence is useful only when its scope matches the specific product being purchased. Before reading any performance data, record:

• The exact catalogue code, such as 110906D or 110911C
• The format (strip, card or cup)
• The individual assay channels in that panel
• The version and date of the instructions for use (IFU) and any performance report

A report prepared for one configuration should not be assumed to cover the whole Multi-Drug Screening Test range. Well-organised drug test technical documentation should state the product code and document version clearly, so reviewers can confirm at once that each document belongs to the selected configuration.

What Should Immunoassay Cross-Reactivity Tables Show?

Immunoassay cross-reactivity describes an assay’s response to compounds other than its reference target or calibrator. Depending on the assay’s design, these responses may contribute to intended drug-class detection or represent unintended reactions.

When JAL Medical provides cross-reactivity information for a panel, check whether each table entry identifies:

• The compound tested
• The channel evaluated
• The concentration tested and its unit
• The observed outcome
• The criterion used to classify that outcome
• How the compound relates to the channel’s target or calibrator
• The conditions and scope of the evaluation

A documented result is different from a broad statement such as “no interference,” which does not show what was tested, at what level or on which channel.

The table should also make clear which responses reflect intended class detection and which are unintended. This matters for channels such as AMP, MET and MDMA, which target related drug classes: buyers need to know which compounds each channel is designed to detect.

How Are Tested Concentrations Reported in Cross-Reactivity Studies?

Concentration data is often the hardest part of a table to interpret. When reviewing concentration information supplied by JAL Medical for a channel, ask:

• Does the reported value show a concentration tested with no observed response, or the concentration that produced a response?
• Are units consistent and clearly defined across the table?
• Was each compound tested at more than one concentration?
• Were samples near the channel’s cutoff included?
• Were the evaluations carried out in urine, the specimen the test is intended for?
• Were replicate numbers and acceptance criteria documented?

Keep two values apart. The cutoff is the threshold for the channel’s target drug or calibrator. The concentration listed for a potential cross-reactant is a separate test condition, and confusing the two leads to misreading.

If cross-reactivity is reported as percentages, ask JAL Medical how each figure was calculated and which reference substance it was measured against.

Why Each Channel of a Multi-Drug Screening Test Kit Needs Its Own Review

Each panel combines several separate assay channels in one strip, card or cup. Each channel targets a different drug or drug class, so evidence for one channel says little about another. For example, data supporting the OPI channel does not describe the behaviour of the BUP, MTD or TRA channels on the same panel.

For each channel in the selected configuration, ask JAL Medical:

• Is there supporting data for every channel you plan to order?
• Which calibrator and cutoff apply to that channel?
• Are the cross-reactivity findings explicitly tied to that cutoff?

A drug-class name on the panel does not reveal the calibrator, the metabolites detected or the coverage of individual compounds within that class. “Benzodiazepines (BZO)” or “Opiates (Morphine, OPI)” describes a target group, not the full list of compounds the channel responds to, so request channel-specific information for the exact panel being purchased.

Review every ordered channel against the facility’s acceptance criteria. Additional scrutiny can focus on channels with greater consequences for clinical or administrative decisions.

What Medication Information Should DOA Urine Screening Tests Documentation Include?

Institutions serve different patient groups and see different medication profiles. The practical task is to compare the substances JAL Medical has evaluated for each channel against the medicines your own patients commonly take, such as those on your formulary or frequent prescribing lists.

Questions to raise include:

• Which prescription and non-prescription substances were evaluated for each channel?
• Were relevant metabolites tested separately from their parent compounds?
• Does the documentation separate cross-reactivity from other forms of interference, such as matrix effects or specimen conditions?

This is particularly relevant for panels that include channels for prescribed medicines, such as TCA, BZO, BUP, MTD and TRA. Detection of a prescribed medicine may be expected; the question is whether other medicines were evaluated for unintended responses on those channels.

General lists of medicines said to cause false positives should not stand in for product-specific data. A patient’s medication history alone cannot establish why a particular result occurred, and any change to prescribed treatment remains a matter for the treating clinician.

How to Identify Gaps in Drug Test Technical Documentation

This review is based on the JAL Medical product page for the test and the brochure downloadable from it (iCARE-One-Step-Multi-Drug-Screening-Test.pdf), as accessed in October 2026. The brochure carries no visible version number or date. Together, these sources describe the assay type, specimen, indicator list, 1–14 indicator range, strip, card and cup formats, catalogue codes and basic operating steps for each format.

The reviewed brochure and product page do not include compound-level cross-reactivity tables, tested cross-reactant concentrations, channel-specific cutoffs, calibrator identities, medication-interference evaluations, study designs or a confirmation pathway. This means only that these details were not included in the reviewed public materials. It does not mean they are unavailable from JAL Medical, which may hold them in a full IFU or technical file. Buyers should ask JAL Medical directly which of these documents exist for the selected configuration.

A gap log helps keep the review organised. Record items such as:

• Missing channels or compounds
• Unspecified concentrations or units
• Unclear outcome definitions
• Missing study methods
• Documents without a version number or date
• Unexplained differences between product versions

Use precise wording in the log. “Not reported” means the document is silent. “Not tested” means the manufacturer confirms no evaluation was done. “Tested with no observed response under stated conditions” is a documented finding with defined limits. These are not interchangeable.

Each open item should go to JAL Medical as a written query and be assigned internally to the laboratory or clinical reviewer best placed to judge it. Whether a remaining gap is acceptable depends on your intended use and your own quality policies.

What Confirmation Pathway Should Follow Drug of Abuse Rapid Screen Tests?

JAL Medical describes the test as a qualitative immunoassay, and its brochure presents results as positive, negative or invalid. Before purchasing, buyers should establish how those screening results fit into the institution’s wider testing process. The reviewed materials do not specify a confirmation method, so clarify:

• How the applicable IFU characterises screening results
• Whether the IFU recommends a particular confirmation approach
• Which findings call for further evaluation under your institution’s protocol
• What confirmatory service is available to you, and which analytes and specimen types it covers
• What reporting, referral and turnaround arrangements apply
• How discrepancies between screening and confirmation are reviewed

A screening result alone does not establish confirmed drug identity, impairment, dose, timing of use or misuse.

A Technical Checklist for Reviewing Multi-Drug Screening Test Suppliers

Requesting Documentation for the iCARE One-Step Multi-Drug Screening Test

An enquiry to JAL Medical is answered most usefully when the buyer states the intended use setting, the catalogue code or panel configuration under consideration, and the confirmation partner already in place. With that context, institutions evaluating DOA testing kits can ask JAL Medical for the current instructions, cross-reactivity information, cutoff details and any medication-related evaluations that apply to that configuration. It is also worth asking how follow-up technical questions should be routed once testing begins.

Conclusion

The wide choice of formats and panel combinations in this range is what makes configuration-specific evidence essential. A completed checklist, gap log and set of written responses from JAL Medical form a record of why a particular configuration was judged suitable for a specific use. Keeping that record on file allows the review to be repeated efficiently whenever the instructions, panel or intended setting change.

Frequently Asked Questions